Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 12 | 2021 | 37 | 3.190 |
Why?
|
| Macaca mulatta | 24 | 2025 | 256 | 2.870 |
Why?
|
| Antibodies, Neutralizing | 12 | 2025 | 214 | 2.830 |
Why?
|
| Antibodies, Viral | 13 | 2022 | 329 | 2.450 |
Why?
|
| Zika Virus | 9 | 2021 | 36 | 1.950 |
Why?
|
| Antibodies, Monoclonal | 9 | 2025 | 870 | 1.820 |
Why?
|
| Simian Immunodeficiency Virus | 12 | 2025 | 81 | 1.580 |
Why?
|
| Dengue Virus | 6 | 2022 | 99 | 1.500 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2024 | 145 | 1.400 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 10 | 2025 | 59 | 1.250 |
Why?
|
| Receptors, Fc | 3 | 2024 | 24 | 1.090 |
Why?
|
| HIV Antibodies | 6 | 2025 | 148 | 1.040 |
Why?
|
| Receptors, CCR5 | 2 | 2024 | 59 | 1.020 |
Why?
|
| Dengue Vaccines | 4 | 2022 | 8 | 0.910 |
Why?
|
| Fetus | 1 | 2024 | 100 | 0.850 |
Why?
|
| SAIDS Vaccines | 6 | 2019 | 22 | 0.830 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2021 | 679 | 0.740 |
Why?
|
| Brucellosis | 6 | 2014 | 8 | 0.690 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2025 | 76 | 0.690 |
Why?
|
| HIV Infections | 6 | 2025 | 976 | 0.650 |
Why?
|
| Animals | 42 | 2025 | 20955 | 0.650 |
Why?
|
| Dependovirus | 3 | 2025 | 718 | 0.630 |
Why?
|
| Neck Injuries | 1 | 2019 | 19 | 0.620 |
Why?
|
| Facial Injuries | 1 | 2019 | 13 | 0.620 |
Why?
|
| Immunoglobulin G | 6 | 2023 | 463 | 0.620 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 42 | 0.610 |
Why?
|
| Burns | 1 | 2019 | 45 | 0.600 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 65 | 0.590 |
Why?
|
| Plasma Cells | 1 | 2017 | 52 | 0.530 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 45 | 0.530 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 57 | 0.520 |
Why?
|
| HIV-1 | 5 | 2025 | 725 | 0.470 |
Why?
|
| Animals, Newborn | 4 | 2025 | 245 | 0.450 |
Why?
|
| Viral Load | 7 | 2021 | 233 | 0.430 |
Why?
|
| Graft Rejection | 3 | 2025 | 302 | 0.420 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 383 | 0.400 |
Why?
|
| Joints | 1 | 2013 | 33 | 0.390 |
Why?
|
| Brucella melitensis | 4 | 2014 | 4 | 0.390 |
Why?
|
| Isoantibodies | 2 | 2023 | 35 | 0.380 |
Why?
|
| Bone and Bones | 1 | 2013 | 140 | 0.360 |
Why?
|
| Pregnancy | 5 | 2024 | 2370 | 0.350 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1019 | 0.340 |
Why?
|
| Host-Pathogen Interactions | 3 | 2021 | 266 | 0.310 |
Why?
|
| Female | 18 | 2025 | 33383 | 0.310 |
Why?
|
| Gene Products, vif | 2 | 2019 | 9 | 0.300 |
Why?
|
| Gene Products, nef | 2 | 2019 | 13 | 0.300 |
Why?
|
| Humans | 27 | 2025 | 64272 | 0.290 |
Why?
|
| Viremia | 4 | 2021 | 44 | 0.280 |
Why?
|
| Simian T-lymphotropic virus 1 | 2 | 2017 | 2 | 0.260 |
Why?
|
| Gene Products, tax | 2 | 2017 | 2 | 0.260 |
Why?
|
| Male | 14 | 2025 | 30322 | 0.260 |
Why?
|
| Thrombopoietin | 1 | 2025 | 11 | 0.230 |
Why?
|
| Abatacept | 1 | 2025 | 66 | 0.230 |
Why?
|
| Journal Impact Factor | 1 | 2025 | 26 | 0.230 |
Why?
|
| Transplantation Conditioning | 1 | 2025 | 102 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 248 | 0.220 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2024 | 16 | 0.220 |
Why?
|
| CD40 Ligand | 1 | 2025 | 159 | 0.220 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2024 | 32 | 0.220 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 329 | 0.220 |
Why?
|
| Immunologic Factors | 1 | 2025 | 109 | 0.220 |
Why?
|
| Immunization, Passive | 1 | 2024 | 96 | 0.220 |
Why?
|
| Models, Animal | 2 | 2021 | 240 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2025 | 285 | 0.210 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2021 | 60 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2021 | 668 | 0.200 |
Why?
|
| Antibody Affinity | 2 | 2021 | 19 | 0.200 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2025 | 270 | 0.190 |
Why?
|
| Genetic Vectors | 2 | 2025 | 887 | 0.190 |
Why?
|
| Immunoglobulin M | 2 | 2023 | 115 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2025 | 356 | 0.180 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2022 | 48 | 0.180 |
Why?
|
| Macaca | 2 | 2021 | 32 | 0.180 |
Why?
|
| Immunity, Cellular | 3 | 2017 | 178 | 0.180 |
Why?
|
| Antilymphocyte Serum | 1 | 2021 | 22 | 0.180 |
Why?
|
| Receptors, IgG | 1 | 2021 | 41 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 34 | 0.170 |
Why?
|
| Coinfection | 1 | 2021 | 58 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2021 | 154 | 0.160 |
Why?
|
| Rectum | 2 | 2019 | 93 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 645 | 0.160 |
Why?
|
| RNA, Viral | 5 | 2019 | 276 | 0.160 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2019 | 4 | 0.150 |
Why?
|
| Immune Sera | 1 | 2019 | 35 | 0.150 |
Why?
|
| Epidemics | 1 | 2019 | 25 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 4 | 2013 | 891 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2019 | 1020 | 0.150 |
Why?
|
| Gene Products, env | 1 | 2018 | 18 | 0.140 |
Why?
|
| Fetal Death | 1 | 2018 | 14 | 0.140 |
Why?
|
| HTLV-I Infections | 1 | 2017 | 3 | 0.140 |
Why?
|
| Mice | 9 | 2025 | 10994 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 39 | 0.130 |
Why?
|
| Herpesviridae | 1 | 2017 | 15 | 0.130 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 38 | 0.130 |
Why?
|
| Immunosuppressive Agents | 3 | 2025 | 381 | 0.130 |
Why?
|
| Dengue | 1 | 2017 | 96 | 0.130 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 119 | 0.130 |
Why?
|
| Deltaretrovirus Infections | 1 | 2016 | 2 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 458 | 0.120 |
Why?
|
| Genomics | 1 | 2019 | 379 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2016 | 126 | 0.120 |
Why?
|
| Mutation | 1 | 2024 | 2633 | 0.120 |
Why?
|
| Adult | 5 | 2019 | 17136 | 0.120 |
Why?
|
| Immune Evasion | 2 | 2017 | 68 | 0.120 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2015 | 21 | 0.120 |
Why?
|
| HEK293 Cells | 1 | 2017 | 626 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 181 | 0.110 |
Why?
|
| Phylogeny | 3 | 2024 | 385 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1561 | 0.110 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 1597 | 0.100 |
Why?
|
| Macrophages | 2 | 2022 | 1053 | 0.100 |
Why?
|
| Virulence Factors | 1 | 2013 | 85 | 0.100 |
Why?
|
| Unfolded Protein Response | 1 | 2013 | 58 | 0.100 |
Why?
|
| Arthritis | 1 | 2013 | 53 | 0.100 |
Why?
|
| Middle Aged | 3 | 2019 | 17923 | 0.100 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 2237 | 0.100 |
Why?
|
| Transplantation, Heterologous | 2 | 2023 | 240 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2621 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2019 | 184 | 0.090 |
Why?
|
| Fimbriae Proteins | 1 | 2012 | 14 | 0.090 |
Why?
|
| Young Adult | 2 | 2019 | 4782 | 0.090 |
Why?
|
| Graft Survival | 2 | 2025 | 297 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2019 | 3318 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2013 | 175 | 0.090 |
Why?
|
| Spleen | 1 | 2013 | 483 | 0.090 |
Why?
|
| Interferon-gamma | 4 | 2017 | 576 | 0.090 |
Why?
|
| Adolescent | 2 | 2019 | 6306 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 182 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 103 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2017 | 617 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 266 | 0.080 |
Why?
|
| Antibody Specificity | 2 | 2021 | 102 | 0.080 |
Why?
|
| Vaccines, Attenuated | 2 | 2022 | 36 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1581 | 0.080 |
Why?
|
| Aedes | 2 | 2019 | 12 | 0.070 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 200 | 0.070 |
Why?
|
| Vaccines, Synthetic | 2 | 2019 | 78 | 0.070 |
Why?
|
| Liver | 1 | 2013 | 868 | 0.070 |
Why?
|
| Brucella abortus | 1 | 2008 | 6 | 0.070 |
Why?
|
| Cytokines | 2 | 2012 | 945 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 775 | 0.070 |
Why?
|
| Cross Reactions | 2 | 2017 | 134 | 0.070 |
Why?
|
| Florida | 2 | 2017 | 49 | 0.070 |
Why?
|
| Viral Vaccines | 2 | 2019 | 54 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2008 | 204 | 0.070 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 116 | 0.060 |
Why?
|
| Genome, Viral | 2 | 2017 | 140 | 0.060 |
Why?
|
| Virus Replication | 2 | 2018 | 324 | 0.060 |
Why?
|
| Drug Discovery | 2 | 2017 | 98 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2025 | 7 | 0.060 |
Why?
|
| Cell Separation | 1 | 2025 | 146 | 0.060 |
Why?
|
| Transplant Recipients | 1 | 2025 | 37 | 0.060 |
Why?
|
| Germinal Center | 1 | 2025 | 39 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2025 | 64 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2008 | 529 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2025 | 181 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2025 | 302 | 0.050 |
Why?
|
| Vaccination | 2 | 2019 | 371 | 0.050 |
Why?
|
| United States | 1 | 2017 | 7923 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 1386 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2016 | 197 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2025 | 517 | 0.050 |
Why?
|
| Primates | 1 | 2024 | 55 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 63 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 783 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2025 | 219 | 0.050 |
Why?
|
| Brazil | 1 | 2022 | 100 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2025 | 572 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 34 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2022 | 150 | 0.040 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2021 | 28 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 22 | 0.040 |
Why?
|
| Swine | 1 | 2022 | 395 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2021 | 32 | 0.040 |
Why?
|
| Glycosylation | 1 | 2021 | 138 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 1570 | 0.040 |
Why?
|
| Vero Cells | 1 | 2021 | 81 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2021 | 85 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 199 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 24 | 0.040 |
Why?
|
| Cuba | 1 | 2019 | 1 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 18 | 0.040 |
Why?
|
| West Indies | 1 | 2019 | 6 | 0.040 |
Why?
|
| Mosquito Control | 1 | 2019 | 8 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 73 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 50 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 705 | 0.040 |
Why?
|
| Travel | 1 | 2019 | 44 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 766 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 668 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 180 | 0.030 |
Why?
|
| Papio anubis | 1 | 2017 | 2 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 26 | 0.030 |
Why?
|
| Americas | 1 | 2017 | 6 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 272 | 0.030 |
Why?
|
| Asia | 1 | 2017 | 27 | 0.030 |
Why?
|
| Africa | 1 | 2017 | 29 | 0.030 |
Why?
|
| Mosquito Vectors | 1 | 2017 | 15 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2017 | 21 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 32 | 0.030 |
Why?
|
| Nervous System Malformations | 1 | 2017 | 13 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 2017 | 103 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 52 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 24 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 42 | 0.030 |
Why?
|
| Alleles | 1 | 2018 | 449 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2017 | 83 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 239 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 234 | 0.030 |
Why?
|
| Papio | 1 | 2016 | 21 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5696 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 519 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 2138 | 0.030 |
Why?
|
| HLA-B27 Antigen | 1 | 2015 | 3 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 313 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1431 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2017 | 266 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 215 | 0.030 |
Why?
|
| Proteome | 1 | 2016 | 155 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 295 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 544 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2016 | 290 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 417 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2013 | 56 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 590 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 1335 | 0.020 |
Why?
|
| Dogs | 1 | 2013 | 332 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 2019 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1999 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 167 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2605 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 608 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2009 | 88 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2177 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2009 | 182 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Epitopes | 1 | 2009 | 292 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 17 | 0.020 |
Why?
|
| Child | 1 | 2017 | 4583 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2008 | 127 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 223 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2008 | 229 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 212 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3449 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 351 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 1619 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1622 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 14663 | 0.010 |
Why?
|